Merck & Co. announces voluntary withdrawal of Vioxx from worldwide market

Published: 2004-10-05 07:00:00

Updated: 2004-10-05 07:00:00

Merck &. Co., Inc. on September 30 announced a voluntary worldwide withdrawal of Vioxx (rofecoxib), its arthritis and acute pain medication. The company's decision, which is effective immediately, is based on new, three-year data from a prospective, randomized, placebo-controlled clinical trial, the APPROVe (Adenomatous Polyp Prevention on VIOXX) trial.

The company said that the trial, which...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.